Aerie Pharma (AERI) Misses Q4 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to Aerie Pharma (AERI) Misses Q4 EPS by 5c

Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update

March 7, 2017 4:01 PM EST

Conference Call and Webcast Today, March 7, at 5:00 p.m. ET

IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2016, along with a general business update.

Aerie Highlights and Outlook

Rhopressa (netarsudil ophthalmic solution) 0.02% NDA (new drug application) filing was resubmitted on February, 28, 2017, with a... More